Ubs Asset Management Americas Inc Day One Biopharmaceuticals, Inc. Transaction History
Ubs Asset Management Americas Inc
- $417 Billion
- Q4 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 75,579 shares of DAWN stock, worth $628,061. This represents 0.0% of its overall portfolio holdings.
Number of Shares
75,579
Previous 65,193
15.93%
Holding current value
$628,061
Previous $908,000
5.4%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding DAWN
# of Institutions
175Shares Held
77.1MCall Options Held
139KPut Options Held
253K-
Atlas Venture Life Science Advisors, LLC6.43MShares$53.4 Million13.44% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.85MShares$48.6 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.76MShares$47.8 Million1.18% of portfolio
-
Braidwell LP Stamford, CT4.87MShares$40.5 Million3.46% of portfolio
-
Black Rock Inc. New York, NY4.53MShares$37.7 Million0.0% of portfolio
About Day One Biopharmaceuticals, Inc.
- Ticker DAWN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 73,461,104
- Market Cap $610M
- Description
- Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...